Ray Dalio Bridgewater Associates
Ray Dalio is the founder of Bridgewater Associates, one of the world’s largest hedge funds, known for its unique “principles-based” culture and systematic investment approach. Dalio’s investment philosophy emphasizes diversified portfolios, risk parity, and the importance of understanding economic cycles in shaping investment decisions. He has authored several books, including “Principles: Life & Work,” in which he details his management philosophies, personal experiences, and life lessons.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$148M |
| 2 |
Mondelez International
MDLZ
|
+$144M |
| 3 |
Johnson & Johnson
JNJ
|
+$64.3M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$53.4M |
| 5 |
Microsoft
MSFT
|
+$51.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$225M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$151M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$91.6M |
| 4 |
Walmart Inc
WMT
|
+$87.7M |
| 5 |
JPMorgan Chase
JPM
|
+$79.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 29.71% |
| 2 | Healthcare | 20.65% |
| 3 | Consumer Discretionary | 10.85% |
| 4 | Financials | 7.63% |
| 5 | Technology | 4.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Revvity
RVTY
$12.8B
| $3.58M | 0.02% |
29,744
+18,629
| +168% | +$2.63M |
|
452
CSX Corp
CSX
$93.1B
| $3.55M | 0.02% |
133,261
-164,313
| -55% | -$5.11M |
|
453
Phreesia
PHR
$773M
| $3.54M | 0.02% |
138,926
-2,988
| -2% | -$74.6K |
|
454
Bio-Rad Laboratories Class A
BIO
$9.42B
| $3.51M | 0.02% |
8,411
+5,178
| +160% | +$2.58M |
|
455
McCormick & Company Non-Voting
MKC
$14.2B
| $3.49M | 0.02% |
48,913
+2,685
| +6% | +$225K |
|
456
Smith & Nephew
SNN
$12.6B
| $3.48M | 0.02% |
150,057
+27,208
| +22% | +$697K |
|
457
Weis Markets
WMK
$1.86B
| $3.48M | 0.02% |
48,775
-1,769
| -3% | -$138K |
|
458
SM Energy
SM
$6.87B
| $3.44M | 0.02% |
+91,399
| New | +$3.6M |
|
459
AES
AES
$10.5B
| $3.4M | 0.02% |
+150,524
| New | +$3.57M |
|
|
RCM
460
DELISTED
R1 RCM Inc. Common Stock
RCM
| $3.4M | 0.02% |
183,410
-34,276
| -16% | -$782K |
|
461
Norfolk Southern
NSC
$75.1B
| $3.38M | 0.02% |
16,120
-7,076
| -31% | -$1.7M |
|
462
Open Text
OTEX
$6.04B
| $3.38M | 0.02% |
+127,051
| New | +$4.49M |
|
463
SkinHealth Systems
SKIN
$85.7M
| $3.33M | 0.02% |
282,690
-3,360
| -1% | -$42.5K |
|
464
Medifast
MED
$141M
| $3.29M | 0.02% |
30,405
-13,714
| -31% | -$1.97M |
|
465
Integer Holdings
ITGR
$4.26B
| $3.23M | 0.02% |
51,987
-46
| -0.1% | -$3.09K |
|
466
Ubiquiti
UI
$34.3B
| $3.2M | 0.02% |
10,904
+6,157
| +130% | +$1.82M |
|
467
Markel Group
MKL
$23.2B
| $3.2M | 0.02% |
2,950
-371
| -11% | -$453K |
|
468
Rush Enterprises Class A
RUSHA
$6.22B
| $3.18M | 0.02% |
+108,714
| New | +$3.5M |
|
469
Kilroy Realty
KRC
$4.42B
| $3.18M | 0.02% |
75,463
-12,907
| -15% | -$651K |
|
470
Unum
UNM
$14.3B
| $3.17M | 0.02% |
81,669
-4,485
| -5% | -$164K |
|
471
Range Resources
RRC
$8.95B
| $3.16M | 0.02% |
+124,978
| New | +$3.78M |
|
472
Progress Software
PRGS
$1.76B
| $3.13M | 0.02% |
73,534
+24,209
| +49% | +$1.12M |
|
473
Boston Properties
BXP
$11.1B
| $3.11M | 0.02% |
41,501
-3,564
| -8% | -$303K |
|
474
Cincinnati Financial
CINF
$27.1B
| $3.11M | 0.02% |
34,679
-4,950
| -12% | -$510K |
|
475
Ingles Markets
IMKTA
$1.67B
| $3.04M | 0.02% |
38,340
-1,202
| -3% | -$109K |
|
Similar funds
Ray Dalio's Q3 2022 Portfolio in Review
As of Q3 2022, Ray Dalio held 1,045 positions worth $19.8B, down 16% from $23.6B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Ray Dalio withdrew a net $2.53B in Q3 2022, closing 179 positions and reducing 498 holdings. Its most notable exit was Medtronic, an estimated $225M position sold in full.
By sector, the portfolio is most concentrated in Consumer Staples at 30% of assets, up from 26% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Ray Dalio opened a new position in Accenture worth $29.3M.
- Ray Dalio's largest Q3 2022 buy was Accenture: 113,811 shares worth $29.3M.
- Ray Dalio added most to Visa in Q3 2022, an estimated $148M increase.
- Ray Dalio's biggest Q3 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $151M.
- Ray Dalio fully exited Medtronic in Q3 2022, selling an estimated $225M.
- Ray Dalio's ten largest holdings make up 32% of its $19.8B portfolio in Q3 2022.
- Ray Dalio opened 60 new positions and closed 179 in Q3 2022.
- Ray Dalio's portfolio value fell 16% quarter-over-quarter to $19.8B.
Based on Bridgewater Associates's 13F filing for Q3 2022, filed 10 Nov 2022.